Glucose-lowering drugs may reduce the risk of developing epilepsy, according to a preliminary study of people with diabetes. The study, published in the medical journal Neurology®, suggests that GLP-1 drugs could be linked to a lower risk of epilepsy. However, it's important to note that the study does not prove causation; it only shows an association. The findings are promising, as people with diabetes are at an increased risk of developing epilepsy later in life. Epilepsy can have significant physical, psychological, and social consequences, and many individuals do not respond to current medications. The study examined a U.S. health database of adults with type 2 diabetes who started taking either a GLP-1 drug or a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor). The GLP-1 drugs included in the study were dulaglutide, liraglutide, and semaglutide. The results showed that 2.35% of participants taking GLP-1 drugs developed epilepsy, compared to 2.41% of those taking DPP-4 inhibitors. After adjusting for factors like age, high blood pressure, and cardiovascular disease, the study found that GLP-1 drug users were 16% less likely to develop epilepsy. The association with a lower risk of epilepsy was strongest with the drug semaglutide. However, the study has limitations, including a lack of information on factors like family history, genetic susceptibility, and alcohol use. Additionally, the study's design and the introduction of tirzepatide after the study period may impact the findings. Further research is needed to confirm these results and explore the potential neurological benefits of GLP-1 drugs.
